Introduction
The APC (adenomatous polyposis coli) tumor suppressor gene has been recognized as the gatekeeper that defends against the initiation of intestinal carcinogenesis. Mutational inactivation of APC actually does occur earlier and more frequently than any other genetic events in intestinal carcinogenesis (Kinzler and Vogelstein, 1996) . Although the product of the APC gene is a multifunctional protein, its functional failure as a component of the degradation machinery of the bcatenin protein seems to be the main cause of its inability to protect against carcinogenesis (Polakis et al., 1999) . b-Catenin protein actually accumulates in intestinal adenoma and adenocarcinoma cells of familial adenomatous polyposis (FAP) patients (Inomata et al., 1996) . Colorectal cancer with the wild-type APC gene often contains a stabilizing mutation in the b-catenin gene (Sparks et al., 1998) , and genetic elimination of exon 3 from the b-catenin gene, which contains the GSK3b phosphorylation sites, resulted in intestinal polyposis in a murine model (Harada et al., 1999) . The role of accumulated b-catenin is not fully understood, but aberrant transactivation of a certain set of genes by the b-catenin and TCF/LEF transcription factor complexes has been implicated (Kikuchi, 2003; Korinek et al., 1997) .
We previously established a rat intestinal epithelial cell clone capable of inducing the stabilized b-catenin protein lacking N-terminal GSK3b phosphorylation sites (IEC6-TetOff b-catenin DN89) by using the tetracycline-inducible promoter . Parental IEC6 cells maintain contact inhibition and anchorage dependency and are not tumorigenic in nude mice (Quaroni et al., 1979; Soubeyran et al., 2001) . IEC6 cells express Musashi-1, a possible stem cell marker of the intestinal epithelium, and retain potentials to differentiate into various cell lineages, including absorptive enterocyte, goblet, endocrine, and Paneth cell (Kedinger et al., 1986; Soubeyran et al., 1999 Soubeyran et al., , 2001 Kayahara et al., 2003) . The b-catenin and T-cell factor/ lymphoid enhacer factor (TCF/LEF) transcription factor complexes have been implicated in the maintenance of undifferentiated intestinal crypt epithelial cells (Theodosiou and Tabin, 2003) . Mice lacking TCF-4 revealed the absence of proliferating compartments in the intestinal crypt (Korinek et al., 1998) , and a recent cDNA microarray study reveled that the TCF-4/ b-catenin complex switches over differentiation toward proliferation of intestinal epithelial cells . IEC6-TetOff b-catenin DN89 cells produced numerous polypoid foci when cultured in confluence for 2-4 weeks with the induction of the stabilized b-catenin DN89 protein . Based on these observations, we consider that IEC6-TetOff b-catenin DN89 is an appropriate model for analysing the first step of carcinogenesis in the intestinal epithelium.
In our earlier study, we investigated the protein expression profile associated with polypoid focus formation of IEC6-TetOff b-catenin DN89 cells . Out of more than 2000 protein spots displayed by fluorescence two-dimensional difference gel electrophoresis (2D-DIGE), only 22 were found to be significantly up-or downregulated 2 weeks after induction of b-catenin DN89 (Seike et al., 2003) . Because aberrant transcriptional regulation of target genes by the b-catenin and TCF-4/LEF complexes precedes these proteomic changes and is the primary event of colorectal carcinogenesis, we focused on the immediate morphological and transcriptional responses of IEC6 cells to the induction of oncogenic b-catenin DN89 protein in the current study.
Results
Morphological alterations of IEC6 cells expressing the stabilized b-catenin IEC6-TetOff b-catenin DN89 cells manifested nearly round or polygonal abundant cytoplasm with welldeveloped intercellular connection when cultured in the presence of doxorubicin (Dox) (without induction of b-catenin DN89) (Figure 1a and c) . Upon the induction of b-catenin DN89 by removing Dox from the culture medium for 96 h, IEC6-TetOff b-catenin DN89 cells became sharply elongated and extended protrusions at cell periphery (Figure 1b and d) . Intercellular connection was loosened and often disappeared (Figure 1d ). Immunofluorescence microscopy revealed that the b-catenin protein was shifted from the intercellular Figure 2f ) and increment of focal contacts (Figure 2d and green in Figure 2f ) along the stress fibers.
In addition to increased focal contacts and actin stress fibers, we noticed that stacking of cells was characteristic of IEC6 cells expressing b-catenin DN89 (Figure 2h ). IEC6-TetOff b-catenin DN89 cells never overlapped each other in the presence of Dox (Figure 2g ).
Gene expression profiles of IEC6 cells expressing the stabilized b-catenin
To identify the molecular mechanisms responsible for the morphological alterations of IEC6 cells expressing b-catenin DN89, we used oligonucleotide microarrays to compare the expression level of approximately 7000 known genes and 17 000 Ests in IEC6-TetOff b-catenin DN89 cells cultured in the presence and absence of Dox. We selected 13 genes whose expression level was altered at least twofold in all three independent experiments (Figures 3 and 4) . The 13 genes consisted of eight genes that were upregulated (Figure 3) upon induction of the stabilized b-catenin protein and five genes that were downregulated (Figure 4) . The global gene expression profiles of IEC6 TetOff control cells, including these 13 genes, did not significantly change upon removal of Dox (data not shown), confirming that the side effects of Dox in the culture medium were negligible.
The results obtained by oligonucleotide microarrays were validated by two independent experiments, and the changes in expression of these 13 genes were confirmed by real-time (top) and conventional (bottom) reverse ∆N89β-catenin ∆N89β-catenin ∆N89β-catenin ∆N89β-catenin ∆N89β-catenin ∆N89β-catenin ∆N89β-catenin ∆N89β-catenin
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Expression of genes regulated by b-catenin DN89 in adenoma tissues of Min mice and FAP patients
Next, we examined the expression of the 11 known genes in adenoma and corresponding normal tissues of Min mice by RT-PCR ( Figure 5 ). Min mice have a germline mutation at codon 850 of the Apc gene, and hundreds of adenomatous polyps spontaneously develop in their small and large intestine (Su et al., 1992) . Because of this, Min mice have come to be recognized as an appropriate animal model of human FAP syndrome. Six of the 11 known genes selected by microarray screening, axis inhibitor-2 (Axin2), insulin-like growth factorbinding protein-2 (Igfbp2), podocalyxin-like protein-1 (Podxl), secreted frizzled-related protein-4 (Sfrp4), immunoglobulin superfamily member 4 (Igsf4), and clusterin (Clu), were found to be upregulated in the adenomatous polyp tissues of Min mice. We investigated the expression of Sfrp1, 2, 3, 4, and 5 by performing RT-PCR with specific primer sets ( Figure 5 ). The results showed that all the Sfrps tended to be increased in the adenoma tissue of Min mice. Immunohistochemistry using available antibodies revealed that the expression of the IGFBP2, PODXL, integrin a6 (ITGA6), AXIN2, serum/glucocorticoidregulated kinase (SGK), and SFRP4 gene products was increased in adenoma cells ( 
TCF/LEF-binding consensus elements in the promoters of identified genes
We searched 3.0-kb promoter regions of their human homolog genes (2.5 kb upstream and 0.5 kb downstream to the transcription initiation site predicted by the oligocapping method) (database of transcriptional start sites, http://dbtss.hgc.jp/index.html) (Suzuki et al., 2004) for TCF/LEF-binding consensus sequences, WWCAAWG (Schwartz et al., 2002) . We examined all these sites except for those of Axin2 in in vivo binding to the native b-catenin and TCF/LEF complexes by chromatin immunoprecipitation (ChIP). All 10 genes contained 1-6 consensus sequences in their promoters (Supplementary Table) . The PODXL gene contains three consensus sequences in its promoter (À1843/À1837, À1319/À1313, and À224/À218). However, one of the regions (À224/À218) could not be examined by PCR because of the high GC content (data not shown).
Anti-b-catenin polyclonal antibody (lanes 1, Figure 7 ), but not control goat IgG (lanes 2, Figure 7 ), precipitated only the fragments containing the consensus sequences in the IGFBP2 (À2436/À2430 and À2215/À2209), CLU (À1660/À1654), and SGK ( þ 189/ þ 195 and þ 482/ Clu Clu/Gapdh
Crtl1/Gapdh
Igsf-4/Gapdh The 1.3-kb registered sequence of the rat Igfbp2 gene promoter (accession number M58560) contains four sequences matched to the consensus TCF/LEF-binding motif, WWCTTWG (À1246/À1240, À1048/À1042, À500/À494, and À430/À4240). Luciferase reporter assays revealed that the construct containing À1292/ À77 of the rat Igfbp2 gene promoter responded to the expression of b-catenin and that removal of À1292/ À934 from the construct abolished responsiveness to stabilized b-catenin (Figure 10a ). The luciferase activity driven by the rat Igfbp2 promoter was suppressed by the expression of the dominant-negative TCF-4 (TCF-4 DN30) in SW48 colorectal cancer cells (Figure 10b ). The region of À2637/À2151 in the human IGFBP2 promoter, which was positive for the ChIP assay (Figure 7 ), contained two consensus TCF/LEF-binding sequences at À2430/À2436 and À2215/À2209. Introduction of mutations (Supplementary Table) significantly reduced the responsiveness to stabilized b-catenin (Figure 10c) .
Regulation of the CLU gene by the TCF/LEF and b-catenin complexes Adenoma tissues of Min mice contained higher amounts of the CLU protein than normal intestinal tissues (Figure 11a ). Immunohistochemistry revealed that the CLU protein was overexpressed in the adenoma tissues of Min mice (Figure 11b ), as reported previously (Chen et al., 2003) .
The constructs of the human CLU gene promoter responded positively to stabilized b-catenin (À1667/ þ 144 Ca; Figure 11c ). The region of À1689/À1501 in the human CLU gene promoter was positive for the ChIP assay and contained one TCF/LEF-binding consensus sequence at À1660/À1654 (Supplementary  Table) . Introduction of a mutation into this site significantly reduced the responsiveness of the CLU gene promoter constructs to stabilized b-catenin (À1667/ þ 144 Mt; Figure 11c ). The construct carrying four repeats of the 20-bp fragment of the human CLU gene promoter (À1667/À1647) responded positively to 
Discussion
To eliminate effects other than the induction of stabilized b-catenin and pinpoint its downstream target genes precisely, we engineered untransformed rat intestinal epithelial IEC6 cells by using the tetracycline-inducible promoter system. IEC6 cells expressing stabilized b-catenin showed morphology of epithelialmesenchymal transition and/or enhanced cell migration (Figure 1a-d) . Similar observations were made in a rat bladder carcinoma cell line expressing the S37/45A b-catenin (Muller et al., 2002) . Furthermore, we observed that IEC6 cells expressing b-catenin DN89 increased focal adhesions and actin stress fibers ( Figure  2a-f) . The most characteristic was overlapping of cells (Figure 2g and h). We previously reported that IEC6 cells expressing b-catenin DN89 showed the formation of polypoid foci when cultured in confluence for 2-4 weeks . These foci were found to be shaped by migrating cells underneath the others , consistent with the current observations. Aberrant inward migration of intestinal epithelial cells has been considered to give rise to nascent adenoma (Oshima et al., 1997) .
To clarify the entire genome network involved in the initiation of intestinal carcinogenesis and to identify target molecules for cancer prevention, we searched for genes whose expression was regulated by accumulation of the b-catenin protein in IEC6 cells. We identified two known negative regulators of the Wnt signaling pathway, Sfrp4 and Axin2. Some of the downstream target genes of the b-catenin and TCF/LEF transcriptional complex seem to participate in the negative feedback loop of the Wnt signaling pathway, and TCF1 and AXIN2 have already been identified as genes belonging to this category (Roose et al., 1999; Lustig et al., 2002) . Transactivation of these genes seems to prevent inappropriate continuous activation of the pathway. SFRPs have also been shown to antagonize the Wnt signaling pathways by binding to either Wnts or frizzled receptors (Rattner et al., 1997) .
A decrease in the expression of the CLU, IGSF4, and SFRP4 genes was expected in the polyp tissues ( Figure 5 ), because these genes were downregulated in the IEC6 cells upon induction of stabilized b-catenin protein (Figure 4) . Furthermore, the fragments of the CLU gene promoter responded positively to b-catenin (Figure 11 ). Although no definite explanation for this discrepancy is currently available, a negative feedback mechanism may be involved; alternatively, this apparent discrepancy may reflect a difference between the in vivo and in vitro or stable and transient expression profiles. IEC6-TetOff b-catenin DN89 was useful for identification of the downstream target genes and proteins regulated by oncogenic b-catenin (Seike et al., 2003) , but the expression level of the induced b-catenin in the IEC6-TetOff b-catenin DN89 cells may not be physiologically appropriate, and/or this particular cell line, IEC6, may regulate gene transcription differently from that in other cell lines and tissues.
CLU (apolipoprotein J (APOJ)), sulfated glycoprotein 2 (SGP2), or testosterone-repressed protein message 2 (TRPM2)) is thought to be involved in the cascade leading to apoptosis (Trougakos and Gonos, 2002) . The CLU gene has been identified as a target of a caudalrelated homeobox gene, Cdx2I (Suh et al., 2001) , and CDX2 has been implicated in the APC/b-catenin signaling pathway (da Costa et al., 1999) . Cdx2 seems to play a role in directing morphogenesis and in maintaining the differentiated phenotype of intestinal epithelial cells. Cdx2-null mice are embryonically lethal, whereas Cdx2 heterozygote mutants develop multiple He et al., 1997) . Recently, the Clu gene product was defined as a new biomarker overexpressed in intestinal tumors of Min mice (Chen et al., 2003) . Consistently, the CLU gene seems to be regulated by oncogenic b-catenin and contain a binding site to the b-catenin and TCF/LEF complexes in its promoter ( Figure 11 ). IGSF4 (tumor suppressor in lung cancer 1 (TSLC1)) was isolated as a gene from the 11q23.2 region that suppresses the tumorigenicity of human non-small cell lung cancer cells in nude mice, and loss of heterozygosity (LOH) in that region is frequently observed in human cancer (Kuramochi et al., 2001) . The PODXL gene encodes a transmembrane glycoprotein that is expressed on podocyte foot processes and is thought to be involved in glomerular filtration (Takeda et al., 2001) . Although PODXL has not been implicated in carcinogenesis, it is a downstream target gene of another tumor suppressor, WT1 (Palmer et al., 2001) . The highly Responses of intestinal epithelial cells to b-catenin Y Naishiro et al frequent association between mutations of the b-catenin (CTNNB1) and WT1 genes was reported in a certain subset of Wilms tumors (Maiti et al., 2000) , suggesting that there may be an unknown molecular link between these two oncoproteins. We observed overexpression of the IGFBP2 mRNA and protein in intestinal adenomas (Figures 5, 6a , and 9c) and IEC6 cells expressing stabilized b-catenin (Figures 3 and 8) . IGFBP2 is related to proliferation and differentiation in colorectal cancer cells (Zhang et al., 1995) . IGFBP2 mRNA has been reported to be increased in sporadic colorectal cancer (Mishra et al., 1998 ). The elevated serum IGFBP2 level of patients with colorectal carcinoma and premalignant adenoma has been expected to serve as a tumor marker for early detection of colorectal carcinogenesis (Miraki-Moud et al., 2001) . The induction of IGFBP2 may be a negative feedback mechanism protective against the oncogenic Wnt signaling pathway, because IGFPB2 was shown to suppress cell proliferation by neutralizing insulin-like growth factors (IGFs) (Corkins et al., 1995) . However, IGFBP2 may have their own functions independent of IGFs. IGFBP2 has been shown to increase the tumorigenic potential of adrenocortical tumor cells (Hoeflich et al., 2001) . Enhanced expression of IGFBP2 was reported to be one of the most frequent alterations in advanced stage of gliomas (Fuller et al., 1999) , and IGFBP2 overexpression enhanced the invasive activity of glioblastoma cells (Wang et al., 2003) . IGFBP2 contains an RGD (Gly-Arg-Asp) motif in its C-terminus. IGFBP2 interacts with integrins aVb3 and a5b1 independently of IGFs (Pereira et al., 2004; Schutt et al., 2004) . The overexpression of IGFBP2, a direct target gene of the b-catenin and TCF4 complex, may somehow support the initiation of carcinogenesis by modulating the cell adhesion and cytoskeleton of intestinal epithelial cells.
Materials and methods
Cell lines and gene expression profiling
A stable clone of rat intestinal epithelial cells capable of inducing stabilized b-catenin protein lacking N-terminal GSK3b phosphorylation sites (IEC6-TetOff b-catenin DN89) under control of the tetracycline-inducible promoter and a relevant mock clone (IEC6-TetOff control) have been described previously . Colorectal cancer cell lines, SW480 and SW48, were purchased from the American Type Culture Collection, Rockville, MD, USA. A cervical cancer cell line HeLa and an embryonal kidney cell line HEK293 were obtained from the Riken cell bank, Tsukuba, Japan. Gene expression profiling with the GeneChip system (Affymetrix Inc., Santa Clara, CA, USA) was performed according to the manufacturer's instructions. Briefly, total RNA was extracted with the RNeasy mini kit (Qiagen, Valencia, CA, USA). Double-strand cDNA was synthesized from DNase I (Ambion Inc., Austin, TX, USA)-treated total RNA by using a T7-(dT) 24 primer. The cDNA was then transcribed in vitro with a BioArray High Yield RNA Transcript Labeling Kit (ENZO Diagnostics Inc., Farmingdale, NY, USA), and the biotinylated cRNA was fragmented and hybridized to the rat GeneChip set (Rat Genome U34 A, B, and C). The stained chips were scanned with a fluorometric scanner (Gene Array Scanner; Hewlett Packard, Palo Alto, CA, USA), and the scanned images were analysed with GeneChip Microarray Suite software (Affymetrix, version 4.0). We repeated the same experiments three times to confirm consistency of the results.
Quantitative RT-PCR
Real-time and conventional RT-PCR was performed using first-strand cDNA synthesized with SuperScript reverse transcriptase II (Invitrogen, Carlsbad, CA, USA). The realtime PCR was performed using SYBR green PCR master mix and the ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA), as instructed by the manufacturer. Relative quantification was achieved by normalizing to the values of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.
Conventional RT-PCR was performed using different sets of primers from the above real-time PCR. PCR products amplified in limited thermal cycles were analysed by agarose gel electrophoresis and ethidium bromide staining. The sequences of all the primer sets used in this study are available upon request.
Male C57BL/6J Min (Apc Min/ þ ) mice were obtained from Jackson Laboratory, Bar Harbor, ME, USA. Total RNA was prepared from normal small and large intestine and polyp tissues with Trizol (Invitrogen) and used for RT-PCR as described above. Animal experiments were reviewed and approved by the ethic committee of the National Cancer Center Research Institute, Tokyo, Japan.
Antibodies, immunoblot, immunofluorescence microscopy, and immunohistochemistry
Anti-b-catenin monoclonal antibody (clone 14) was purchased from BD Transduction Laboratories, San Diego, CA, USA. Anti-IGFBP2 (M-18), anti-PODXL (K-19), anti-ITGA6 (N-19), anti-AXIN2 (M-20), anti-SGK (C-20), anti-CLU (M-18), anti-b-catenin (C-18), and anti-actin (C-11) polyclonal antibodies were purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA. Anti-SFRP4 polyclonal antibody was raised against a synthesized peptide, CQWEERL-QEQRRTVQDKKK. Immunohistochemistry and immunoblot analyses were performed as previously described (Yamada et al., 2000 . Formalin-fixed paraffin-embedded tissues from 10 FAP and 28 sporadic colorectal cancer patients as well as Min mice were used. For immunofluorescence microscopy, cells fixed with 4% paraformaldehyde were incubated with anti-paxillin or anti-b-catenin antibody (BD Transduction) and then with anti-mouse IgG Alexa Fluor 488 (Invitrogen). Filamentous actin fibers were visualized with Alexa Fluor 594 phalloidin (Invitrogen).
ChIP
To identify the promoter regions of genes bound to the TCF/ LEF and b-catenin complexes, ChIP assays were performed using the ChIP kit from Upstate Biotechnology, Lake Placid, NY, USA, according to the manufacturer's protocol. Briefly, 2 Â 10 6 SW480 cells were crosslinked with 1% formaldehyde for 10 min. Sonicated cell supernatant was immunoprecipitated using anti-b-catenin polyclonal antibody or normal goat IgG (Santa Cruz). Precipitates were treated with proteinase K and DNA was extracted with phenol/chloroform and ethanol precipitation. In brief, 200-800-bp regions containing the TCF/LEF-binding consensus sequences were amplified by PCR (Supplementary Table) . Sequences of PCR primers are available upon request.
Luciferase reporter assays
Serial fragments of the rat Igfbp2 gene promoter (Brown and Rechler, 1990) were amplified from genomic DNA of native IEC6 cells by PCR and fused upstream of the firefly luciferase gene in pGL3-basic (Promega, Madison, WI, USA). Fragments (À2443/À2202) of the human IGFBP2 promoter with and without mutations in one or both of two TCF/LEFbinding consensus sequences (À2436/À2430 and À2215/ À2209) (Supplementary Table) were cloned into pGL3-promoter (Promega). Fragments of (À1667/ þ 144) of the human CLU promoter with and without a mutation at À1650/ À1654 were cloned into pGL3-basic. Four tandem repeats of the human CLU promoter fragments (À1667/À1647) with and without a mutation at À1650/À1654 (Supplementary Table) were cloned into pGL3-promoter.
b-Catenin cDNA lacking its N-terminal 131 amino acids was amplified by PCR and fused into the downstream portion of the enhanced green fluorescence protein (EGFP) gene of pEGFP-C1 (BD Biosciences Clontech, Palo Alto, CA, USA) (pEGFP-b-catenin DN131). pEGFP-TCF-4 DN30 has been described previously (Yamada et al., 2000) .
The composition of all constructs was confirmed by sequencing. Details of the procedures used for plasmid construction are available upon request. A luciferase assay was performed using the dual luciferase reporter assay system (Promega) and Renilla luciferase activity was used as an internal control .
